| Literature DB >> 35735820 |
Kakeru Hashimoto1, Akihiro Hirashiki2, Kenichi Ozaki1, Koki Kawamura1, Junpei Sugioka1, Shunya Tanioku1, Kenji Sato1, Ikue Ueda1, Naoki Itoh1, Kenichiro Nomoto2, Manabu Kokubo2, Atsuya Shimizu2, Izumi Kondo1.
Abstract
We examined whether adding robot-supported balance exercises to cardiac rehabilitation improves the ability to balance in older adults with cardiovascular disease (CVD). We conducted a prospective study in 52 older adults who had been hospitalized for worsening CVD. Once weekly for four months, for a total of sixteen sessions as outpatients, the subjects used a Balance Exercise Assist Robot (BEAR) to perform balance exercises and an ergometer for aerobic exercises. Participants' mean age was 76.9 ± 6.8 years (range, 65-95 years), and their mean brain natriuretic protein level was 164.0 ± 190.0 pg/mL. After the intervention, participants showed significant improvements in gait speed (before, 1.06 ± 0.33 m/s; after, 1.23 ± 0.30 m/s; p < 0.001), Short Physical Performance Battery score (before, 10.02 ± 2.25; after, 10.88 ± 1.79; p ˂ 0.001), timed up-and-go (before, 11.11 ± 5.07 s; after, 9.45 ± 3.45 s; p ˂ 0.001), and knee extension (before, 26.97 ± 11.78 kgf; after, 30.13 ± 13.04 kgf; p = 0.001). Cardiac rehabilitation including exercises using BEAR improved physical functioning and the ability to balance in older adults with CVD. Frail and prefrail patients improved, whereas robust ones did not change.Entities:
Keywords: balance exercise assist robot; cardiac rehabilitation; cardiovascular disease; frailty; older adults; robotic rehabilitation
Year: 2022 PMID: 35735820 PMCID: PMC9224750 DOI: 10.3390/jcdd9060191
Source DB: PubMed Journal: J Cardiovasc Dev Dis ISSN: 2308-3425
Figure 1Balance Exercise Assist Robot (BEAR). The BEAR moves backward–forward and left–right according to shifts in the operator’s center of gravity. These movements can be incorporated into balance exercises by playing 3 games: (A) a skiing game, which involves using left–right movement; (B) a rodeo game, which requires responses to disturbance stimuli from the BEAR; and (C) a tennis game, which responds to forward–backward movement.
Figure 2Flow chart of participant inclusion. Of the 127 patients admitted to the cardiology department of our hospital between August 2019 and December 2019, 52 were included in the study. CR, cardiac rehabilitation.
Clinical characteristics of study participants (n = 52).
| Age (years) | 76.9 | ± | 6.8 |
| Sex (male, %) | 53.8 | ||
| Body mass index (kg/m2) | 22.7 | ± | 3.3 |
|
| |||
| Diabetes mellitus ( | 8 (15.4) | ||
| Dyslipidemia ( | 17 (32.4) | ||
| Tobacco users ( | 1 (1.9) | ||
|
| |||
| Worsening heart failure ( | 46 (88.4) | ||
| Non-ischemic cardiomyopathy ( | 2 (3.8) | ||
| Ischemic heart disease ( | 15 (28.8) | ||
| Tachycardia-induced ( | 12 (23.1) | ||
| Atrial fibrillation/Atrial flutter ( | 11 (21.2) | ||
| Implantable cardioverter defibrillator ( | 1 (1.9) | ||
| Bradycardia; Implanted pacemaker ( | 5 (7.7) | ||
| Valvular ( | 4 (7.7) | ||
| Post TAVI ( | 3 (5.9) | ||
| Post MVR ( | 1 (1.9) | ||
| Hypertension ( | 4 (7.7) | ||
| Others ( | 4 (9.6) | ||
| Aortic disease ( | 2 (3.8) | ||
| Atrial septal defect ( | 2 (3.8) | ||
| Post PCI/CABG ( | 6 (11.6) | ||
|
| |||
| Diuretics ( | 20 (38.5) | ||
| Tolvaptan ( | 8 (15.4) | ||
| ACE-I/ARB ( | 23 (44.2) | ||
| β blocker ( | 24 (46.2) | ||
| Spironolactone ( | 6 (21.1) | ||
| Anticoagulant ( | 25 (48.1) | ||
| Antiplatelet agent ( | 25 (48.1) | ||
|
| |||
| BNP (pg/mL) | 164.0 | ± | 190.9 |
| Hemoglobin (mg/dL) | 12.8 | ± | 1.7 |
| Total protein (g/dL) | 6.8 | ± | 0.6 |
| Albumin (g/dL) | 3.9 | ± | 0.5 |
| Total cholesterol (mg/dL) | 173.8 | ± | 37.1 |
| eGFR (mL/min/1.73 m2) | 63.4 | ± | 17.0 |
|
| |||
| Left atrial dimension (mm) | 40.6 | ± | 9.3 |
| LVEF (%) | 57.7 | ± | 12.0 |
| < 40% ( | 5 (9.6) | ||
| 41–50% ( | 4 (7.7) | ||
| E/e′ | 14.3 | ± | 5.4 |
|
| |||
| Respiratory exchange ratio | 1.2 | ± | 0.1 |
| Maximal workload (W) | 58.6 | ± | 26.1 |
| Predicted peak VO2 (%) | 62.7 | ± | 17.5 |
|
| |||
| J-CHS (robust/prefrail/frail) (%) | 7.7/63.5/28.8 | ||
|
| |||
| Depressive symptoms ( | 4 (7.7) | ||
| Educational level (years) | 11.8 | ± | 2.4 |
ACE-I/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; E/e′, ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; J-CHS, Japanese version of the Cardiovascular Health Study criteria; LVEF, left ventricular ejection fraction; MVR, mitral valve reconstruction; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation. Depressive symptoms: the number of participants with GDS of 10 points or more where applicable, data are given as means ± SD.
BEAR effects.
| Baseline | After 4 Months |
| |||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Peak VO2 (mL/min/kg) | 14.09 | ± | 3.79 | 14.53 | ± | 3.88 | 0.222 | ||
| Gait speed (m/s) | 1.06 | ± | 0.33 | 1.23 | ± | 0.30 | <0.001 | ||
| SPPB (points) | 10.02 | ± | 2.25 | 10.88 | ± | 1.79 | ˂0.001 | ||
| TUG (s) | 11.11 | ± | 5.07 | 9.45 | ± | 3.45 | ˂0.001 | ||
| Knee extension (kgf) | 26.97 | ± | 11.78 | 30.13 | ± | 13.04 | 0.001 | ||
| FES-I (points) | 22.91 | ± | 8.16 | 21.45 | ± | 7.17 | 0.139 | ||
| GDS (points) | 2.90 | ± | 3.38 | 2.21 | ± | 2.76 | 0.057 | ||
| MNA-SF (points) | 9.48 | ± | 2.37 | 12.03 | ± | 2.05 | <0.001 | ||
| LVEF (%) | 59.16 | ± | 9.88 | 58.58 | ± | 9.93 | 0.366 | ||
| E/e’ | 14.03 | ± | 4.32 | 13.77 | ± | 4.73 | 0.638 | ||
| BNP (pg/mL) | 29.79 | ± | 10.26 | 26.71 | ± | 9.92 | 0.264 | ||
|
| |||||||||
| Peak VO2 (mL/min/kg) | 15.08 | ± | 3.68 | 15.59 | ± | 3.86 | 0.231 | ||
| Gait speed (m/s) | 1.14 | ± | 0.29 | 1.29 | ± | 0.29 | ˂0.001 | ||
| SPPB (points) | 10.72 | ± | 1.67 | 11.14 | ± | 1.66 | 0.090 | ||
| TUG (s) | 9.54 | ± | 2.86 | 8.73 | ± | 2.69 | 0.008 | ||
| Knee extension (kgf) | 27.89 | ± | 11.88 | 32.33 | ± | 13.31 | 0.003 | ||
| FES-I (points) | 19.56 | ± | 3.97 | 19.48 | ± | 3.69 | 0.899 | ||
| GDS (points) | 1.50 | ± | 1.46 | 1.27 | ± | 1.20 | 0.394 | ||
| MNA-SF (points) | 9.78 | ± | 2.65 | 11.83 | ± | 2.23 | 0.005 | ||
| LVEF (%) | 60.76 | ± | 8.83 | 60.04 | ± | 7.01 | 0.412 | ||
| E/e’ | 12.87 | ± | 3.94 | 12.98 | ± | 3.39 | 0.839 | ||
| BNP (pg/mL) | 113.72 | ± | 136.58 | 142.00 | ± | 170.79 | 0.254 | ||
|
| |||||||||
| Peak VO2 (mL/min/kg) | 12.64 | ± | 3.64 | 12.49 | ± | 3.37 | 0.875 | ||
| Gait speed (m/s) | 0.79 | ± | 0.25 | 1.05 | ± | 0.27 | ˂0.001 | ||
| SPPB (points) | 8.47 | ± | 2.72 | 10.20 | ± | 2.14 | 0.004 | ||
| TUG (s) | 15.09 | ± | 6.80 | 11.46 | ± | 4.35 | 0.004 | ||
| Knee extension (kgf) | 18.73 | ± | 8.29 | 21.32 | ± | 9.75 | 0.042 | ||
| FES-I (points) | 29.79 | ± | 10.26 | 26.71 | ± | 9.92 | 0.264 | ||
| GDS (points) | 6.07 | ± | 4.25 | 4.33 | ± | 3.92 | 0.092 | ||
| MNA-SF (points) | 8.92 | ± | 2.19 | 12.33 | ± | 1.78 | <0.001 | ||
| LVEF (%) | 54.86 | ± | 12.13 | 54.12 | ± | 14.34 | 0.499 | ||
| E/e’ | 17.15 | ± | 3.98 | 16.05 | ± | 7.21 | 0.538 | ||
| BNP (pg/mL) | 284.50 | ± | 259.78 | 203.50 | ± | 171.94 | 0.264 | ||
BNP, brain natriuretic peptide; E/e’, ratio of transmitral Doppler early filling velocity to tissue Doppler early diastolic mitral annular velocity; FES-I, Fall Efficacy Scale—nternational; GDS, Geriatric Depression Scale; knee extension, muscle strength of knee extension; LVEF, left ventricular ejection fraction; MNA-SF, Mini Nutritional Assessment—Short Form; peak VO2, peak oxygen uptake; SPPB, Short Physical Performance Battery; TUG, timed up-and-go. Baseline: just before discharge, after patients had been medically stabilized. After 4 months: 4 months after beginning CR intervention including BEAR exercises.
Figure 3Intervention effect of CR including BEAR exercises (all patients). Changes in 10 m gait test (gait speed), Short Physical Performance Battery score (SPPB), timed up-and-go (TUG) test, muscle strength of knee extension (knee extension), and fear of falling (Fall Efficacy Scale—International, FES-I).
BEAR effects in participants according to sex.
| Men ( | Women ( | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | After 4 Months |
| Baseline | After 4 Months |
| ||||||||||||
| Peak VO2 (mL/min/kg) | 14.46 | ± | 4.14 | 14.99 | ± | 4.26 | 0.148 | 13.63 | ± | 3.34 | 13.95 | ± | 3.37 | 0.885 | |||
| Gait speed (m/s) | 1.11 | ± | 0.33 | 1.25 | ± | 0.28 | 0.001 | 1.00 | ± | 0.33 | 1.20 | ± | 0.32 | <0.001 | |||
| SPPB (points) | 10.31 | ± | 1.72 | 11.08 | ± | 1.83 | 0.003 | 9.70 | ± | 2.74 | 10.65 | ± | 1.75 | 0.029 | |||
| TUG (s) | 9.98 | ± | 4.30 | 8.76 | ± | 3.07 | 0.002 | 12.39 | ± | 5.64 | 10.23 | ± | 3.74 | 0.010 | |||
| Knee extension (kgf) | 33.96 | ± | 11.20 | 37.52 | ± | 12.43 | 0.007 | 19.33 | ± | 6.75 | 21.74 | ± | 7.55 | 0.048 | |||
| FES-I (points) | 22.00 | ± | 6.78 | 20.46 | ± | 5.52 | 0.141 | 24.00 | ± | 9.64 | 22.65 | ± | 8.76 | 0.456 | |||
| GDS (points) | 2.36 | ± | 2.86 | 1.68 | ± | 1.68 | 0.263 | 3.48 | ± | 3.85 | 2.78 | ± | 3.54 | 0.073 | |||
| MNA-SF (points) | 10.18 | ± | 1.98 | 12.00 | ± | 2.06 | 0.012 | 8.75 | ± | 2.59 | 12.06 | ± | 2.11 | <0.001 | |||
| LVEF (%) | 56.37 | ± | 11.36 | 55.24 | ± | 10.71 | 0.230 | 62.74 | ± | 6.13 | 62.87 | ± | 6.95 | 0.885 | |||
| E/e’ | 12.90 | ± | 4.19 | 12.73 | ± | 3.99 | 0.813 | 15.67 | ± | 4.06 | 15.28 | ± | 5.39 | 0.662 | |||
| BNP (pg/mL) | 156.69 | ± | 216.24 | 164.19 | ± | 199.62 | 0.814 | 176.52 | ± | 172.54 | 137.33 | ± | 119.32 | 0.214 | |||
All abbreviations are as in Table 2.